Expression Of Survivin, Cyclooxygenase-2 And Vascular Endothelial Growth Factor And Their Prognostic Significance In Human Gastric Carcinoma

Objective To investigate the expression of Survivin, COX-2, and VEGF in chronic atrophic gastritis, gastric mucosal atypical hyperplasia, and early and middle stage of gastric carcinoma, as well as the relationship between expression of Survivin, COX-2, VEGF, and prognostic significance of Survivin, COX-2, VEGF. Methods 53 patients with early and middle stage of gastric carcinoma who underwent surgical resection between 1992 and 2002 were followed up. Expression of Survivin, COX-2, VEGF was examined by S-P immunohistochemistry in 93 archival paraffin-embedded tissue specimens and control groups. The relationship of Survivin, COX-2, VEGF, and MVD with clinicopathologic factors and prognosis was analysed by SPSS V12.0 for Windows software. Results The follow-up rates of early gastric carcinoma and middle stage of gastric carcinoma were 75.6%(31/41) and 88.0%(22/25), respectively. 5-year survival rates of early and middle stage of gastric carcinoma were 95.2% and 63.6%, respectively. Expression of Survivin and COX-2 was significantly higher in mucosal atypical hyperplasia than that in chronic atrophic gastritis (P<0.05). Compared with paired noncancerous specimens, Survivin and COX-2 levels in carcinoma tissue were significantly higher (P<0.05). Expression of VEGF and MVD value in carcinoma tissue was significantly higher than those in noncancerous specimens and correlated with depth of invasion (P<0.05). The MVD value was much higher in Survivin (+) group and VEGF(+) group than that in Survivin (-) group and VEGF(-) group (P<0.05).